Abbott to Pay $384 Million Settlement Over Contaminated Infant Formula

Key Facts

In a move reflecting the significant legal risks facing the healthcare sector, Abbott Laboratories has agreed to pay over $384 million to resolve allegations concerning contaminated infant formula. According to reports, the settlement was reached with the U.S. Department of Justice to address investigations into the safety and contamination of the company's formula products. This agreement aims to resolve a long-standing legal overhang that has impacted the company's operational focus.

The financial penalty represents a notable hit to the company's balance sheet, though it provides closure to a protracted regulatory investigation. Per market data, ABT stock stood at $101.95 at the close of September 11, 2026, having traded between a day low of $101.49 and a high of $104.18. This settlement highlights the ongoing scrutiny of manufacturing standards within the consumer-health industry and the associated litigation costs for mega-cap firms.

Investors should watch the $101.49 support level, which marked the day's low at the close of September 11, 2026, to gauge market sentiment following the settlement news. While the upcoming economic calendar shows no immediate catalysts specifically for Abbott, the focus will remain on the company's ability to restore consumer trust and manage the impact of this substantial payout on its future earnings.